{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T12:11:48Z","timestamp":1715602308276},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"17","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,9,1]]},"DOI":"10.2146\/ajhp100008","type":"journal-article","created":{"date-parts":[[2010,8,18]],"date-time":"2010-08-18T18:48:56Z","timestamp":1282157336000},"page":"1430-1437","source":"Crossref","is-referenced-by-count":11,"title":["Pattern of clopidogrel use in hospitalized patients receiving percutaneous coronary interventions"],"prefix":"10.1093","volume":"67","author":[{"given":"Bonnie B.","family":"Dean","sequence":"first","affiliation":[{"name":"Cerner LifeSciences, Beverly Hills, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsing-Ting","family":"Yu","sequence":"additional","affiliation":[{"name":"Cerner LifeSciences, Beverly Hills, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jay P.","family":"Bae","sequence":"additional","affiliation":[{"name":"Global Health Outcomes, Eli Lilly & Company, Indianapolis, IN."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne","family":"Fiske","sequence":"additional","affiliation":[{"name":"Cerner LifeSciences."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Meadows","sequence":"additional","affiliation":[{"name":"U.S. Outcomes Research, Global Health Outcomes, Eli Lilly & Company."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Xiong","sequence":"additional","affiliation":[{"name":"Cerner LifeSciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew F.","family":"Emons","sequence":"additional","affiliation":[{"name":"Cerner LifeSciences"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","reference":[{"key":"key\n\t\t\t\t2019041104265138900_b1-0671430","volume-title":"Heart disease and stroke statistics\u20142009 update","author":"American Heart Association","year":"2009"},{"key":"key\n\t\t\t\t2019041104265138900_b2-0671430","doi-asserted-by":"crossref","first-page":"123","DOI":"10.7326\/0003-4819-139-2-200307150-00012","article-title":"Management of patients undergoing percutaneous coronary revascularization","volume":"139","author":"Levine","year":"2003","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t2019041104265138900_b3-0671430","unstructured":"Plavix prescribing information. http:\/\/products.sanofi-aventis.us\/plavix\/plavix.html (accessed 2009 May 8)."},{"key":"key\n\t\t\t\t2019041104265138900_b4-0671430","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1161\/01.CIR.0000160869.75810.98","article-title":"Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention","volume":"111","author":"Hochholzer","year":"2005","journal-title":"Circulation"},{"key":"key\n\t\t\t\t2019041104265138900_b5-0671430","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.amjcard.2008.03.073","article-title":"Comparison of higher clopidogrel loading and maintenance dose to standard dose on platelet function and outcomes after percutaneous coronary intervention using drug-eluting stents","volume":"102","author":"Abuzahra","year":"2008","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t2019041104265138900_b6-0671430","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.amjcard.2007.05.048","article-title":"Meta-analysis appraising high clopidogrel loading in patients undergoing percutaneous coronary intervention","volume":"100","author":"Lotrionte","year":"2007","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t2019041104265138900_b7-0671430","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.amjcard.2006.03.054","article-title":"Onset and offset of platelet inhibition after high-dose clopidogrel loading and standard daily therapy measured by a point-of-care assay in healthy volunteers","volume":"98","author":"Price","year":"2006","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t2019041104265138900_b8-0671430","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.288.19.2411","article-title":"Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial","volume":"288","author":"Steinhubl","year":"2002","journal-title":"JAMA"},{"key":"key\n\t\t\t\t2019041104265138900_b9-0671430","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.amjcard.2007.09.089","article-title":"Effect of clopidogrel pretreatment on angiographic and clinical outcomes in patients undergoing primary percutaneous coronary intervention for ST-elevation acute myocardial infarction","volume":"101","author":"Lev","year":"2008","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t2019041104265138900_b10-0671430","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.jacc.2005.10.047","article-title":"Optimal timing for the initiation of pre-treatment with 300 mg clopidogrel before percutaneous coronary intervention","volume":"47","author":"Steinhubl","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t2019041104265138900_b11-0671430","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ahj.2006.10.030","article-title":"Effect of timing of clopidogrel administration on 30-day clinical outcomes: 300-mg loading dose immediately after coronary stenting versus pretreatment 6 to 24 hours before stenting in a large unselected patient cohort","volume":"153","author":"Szuk","year":"2007","journal-title":"Am Heart J"},{"key":"key\n\t\t\t\t2019041104265138900_b12-0671430","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1067\/mhj.2003.109","article-title":"Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: the Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial","volume":"145","author":"Gurbel","year":"2003","journal-title":"Am Heart J"},{"key":"key\n\t\t\t\t2019041104265138900_b13-0671430","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1161\/CIRCULATIONAHA.109.192663","article-title":"2009 focused updates: ACC\/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC\/AHA\/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"120","author":"Kushner","year":"2009","journal-title":"Circulation"},{"key":"key\n\t\t\t\t2019041104265138900_b14-0671430","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1016\/j.jacc.2009.11.003","article-title":"National efforts to improve door-to-balloon time results from the Door-to-Balloon Alliance","volume":"54","author":"Bradley","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t2019041104265138900_b15-0671430","unstructured":"U.S. Department of Health and Human Services, Office for Civil Rights. HIPAA medical privacy\u2014national standards to protect the privacy of personal health information. https:\/\/www.cms.gov\/HIPAAGenInfo\/Downloads\/HIPAALaw.pdf (accessed 2010 Jun 23)."},{"key":"key\n\t\t\t\t2019041104265138900_b16-0671430","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1161\/CIRCULATIONAHA.105.536276","article-title":"Loading, pretreatment, and interindividual variability issues with clopidogrel dosing","volume":"111","author":"Bates","year":"2005","journal-title":"Circulation"},{"key":"key\n\t\t\t\t2019041104265138900_b17-0671430","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.ahj.2008.07.026","article-title":"Design and rationale of CURRENT-OASIS 7: a randomized, 2 \u00d7 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy","volume":"156","author":"Mehta","year":"2008","journal-title":"Am Heart J"},{"key":"key\n\t\t\t\t2019041104265138900_b18-0671430","unstructured":"Double doses of clopidogrel better than standard doses for heart patients undergoing angioplasty, an international study finds. European Society of Cardiology Congress2009. www.escardio.org\/about\/press\/press-releases\/esc09-barcelona\/Pages\/esc-2009-Mehta-Current%20Oasis%207.aspx (accessed 2010 Mar 16)."},{"key":"key\n\t\t\t\t2019041104265138900_b19-0671430","first-page":"e148","article-title":"ACC\/AHA 2007 guidelines for the management of patients with unstable angina\/non ST-elevation myocardial infarction: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina\/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine","volume":"116","author":"Anderson","year":"2007","journal-title":"Circulation"},{"key":"key\n\t\t\t\t2019041104265138900_b20-0671430","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1056\/NEJMoa0901316","article-title":"Early versus delayed, provisional eptifibatide in acute coronary syndromes","volume":"360","author":"Giugliano","year":"2009","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041104265138900_b21-0671430","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1161\/01.STR.0000169922.79281.a5","article-title":"Association of a functional polymorphism in the clopidogrel target receptor gene, P2Y12, and the risk for ischemic cerebrovascular events in patients with peripheral artery disease","volume":"36","author":"Ziegler","year":"2005","journal-title":"Stroke"},{"key":"key\n\t\t\t\t2019041104265138900_b22-0671430","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1161\/CIRCULATIONAHA.106.675991","article-title":"Variable platelet response to aspirin and clopidogrel in atherothrombotic disease","volume":"115","author":"Maree","year":"2007","journal-title":"Circulation"},{"key":"key\n\t\t\t\t2019041104265138900_b23-0671430","unstructured":"Plavix prescribing information. sanofi-aventis. http:\/\/products.sanofi-aventis.us\/PLAVIX\/PLAVIX.html (accessed 2010 Mar 19)."},{"key":"key\n\t\t\t\t2019041104265138900_b24-0671430","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jacc.2007.06.064","article-title":"Influence of omeprazole on the anti-platelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study","volume":"51","author":"Gilard","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t2019041104265138900_b25-0671430","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1001\/jama.2009.261","article-title":"Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome","volume":"301","author":"Ho","year":"2009","journal-title":"JAMA"},{"key":"key\n\t\t\t\t2019041104265138900_b26-0671430","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/S0140-6736(09)61525-7","article-title":"Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials","volume":"374","author":"O\u2019Donoghue","year":"2009","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019041104265138900_b27-0671430","unstructured":"CathPCI Registry. NCDR Cath PCI Registry v4.3.1 coder\u2019s data dictionary. www.ncdr.com\/WebNCDR\/NCDRDocuments\/CathPCI_v4_CodersDictionary_4.3.1.pdf (accessed 2010 Mar 16)."}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/67\/17\/1430\/28344956\/ajhp1430.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T22:52:26Z","timestamp":1559429546000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/67\/17\/1430\/5130679"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9,1]]},"references-count":27,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2010,9,1]]}},"URL":"https:\/\/doi.org\/10.2146\/ajhp100008","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2010,9,1]]},"published":{"date-parts":[[2010,9,1]]}}}